Empagran strikes back
This article was originally published in The Tan Sheet
Executive Summary
Washington, D.C. federal appeals court will revisit vitamin price-fixing claims in Empagran v. Hoffman-La Roche, on remand from Supreme Court. While the highest court ruled the foreign firms could not make U.S. antitrust claims for damages sustained in foreign countries, it noted Empagran et al. presented an alternative "global market" claim that was not addressed in the appeal (1"The Tan Sheet" June 21, 2004, p. 12). That claim maintains the allegedly anticompetitive activities that led to the injuries could not have occurred without a domestic effect. The appellate court will hear the claim and plans to set a schedule for briefing and oral argument, the court announces Nov. 2...
You may also be interested in...
Supreme Court Vitamin Antitrust Ruling Throws Foreign Claims Out
Foreign firms injured in commerce occurring "significantly" in foreign markets will not be able to pursue antitrust claims in the U.S., the Supreme Court ruled June 14
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.